Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm

This article was originally published in The Pink Sheet Daily

Executive Summary

Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.

You may also be interested in...



With Celgene Deal, Forma Makes First Foray Into Clinical Development

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.

Lacking "Mediator," EC Tightens Pharmacovigilance Proposals

European Commission's surprise update of the pharmacovigilance rules is included in its review of the information to patients legislation, but industry's biggest concern may be the failure to address the role of social media.

U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs

Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.

Related Content

Topics

UsernamePublicRestriction

Register

PS072883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel